Trial intelligence / Profile preview

MOMENT: Inebilizumab in Primary Membranous Nephropathy

NCT07851220Phase 3

Key facts

Status: Recruiting
Start: Oct 2026
Primary completion: Sep 2031
Countries: 1
Sponsor: Amgen

Drugs: inebilizumab
Conditions: primary membranous nephropathy (PMN)

Overview

Phase 3, randomised, open-label trial of inebilizumab in primary membranous nephropathy (PMN) (2 arms), sponsored by Amgen. Primary endpoint: Complete Remission at 104 weeks. Started Oct 2026; status: recruiting.

Design

2 arms

Study design: RandomizedOpen-label

Inebilizumab
Participants will receive inebilizumab via intravenous (IV) infusion
Tacrolimus
Participants will receive tacrolimus orally.

Who it enrols

Adults with primary membranous nephropathy, UPCR >=3.5, on stable ACEi/ARB, with eGFR >=40, excluding those with secondary MN, severe infections, or recent immunosuppressive therapies.

Endpoints

Primary

Complete Remission104 weeks

Secondary

Complete Remission or Partial Remission104 weeks
Time to First Complete Remission104 weeks
Time to First Complete Remission or Partial Remission104 weeks
Duration of Complete Remission104 weeks
Anti-Phospholipase A2 Receptor Antibody Levels104 weeks
Adverse Events194 weeks
Anti-inebilizumab Antibodies104 weeks
Serum Concentrations of Inebilizumab160 weeks

Beyond the preview

Go deeper on NCT07851220.

Full results, competitive context and analysis are in the Gosset platform.

Full results & analysis

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT07851220.